Development and target identification of anticancer and antifungal agents for new therapeutic modalities

The emergence of resistant strains in antifungal diseases in recent years, due to global warming and the overuse of drugs, has led to a rapid increase in the number of patients, and has become a serious public health problem. There are only three compound classes of antifungal drugs that are currently in use and therefore the development of drugs effective against resistant strains is urgently needed.

The number of cancer patients is increasing rapidly as the world’s population ages. The current anticancer drugs used for cancer treatment have many off-target proteins involved in side-effects in addition to the efficacy target proteins. Therefore, there is a need for the development of new anticancer drugs with higher specificity and safety.

This research project aims to develop drug seeds for the treatment of fungal infections and cancer through collaboration with overseas researchers who possess unique methodologies.